Physician profile
Jordan E Heath
NPI 1114360930
$5,062.80
in general payments reported to CMS, 2019-2025
17 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.33 · 2022: $359 · 2023: $1,473 · 2024: $1,591 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,573 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,573.30 |
| Education | $119.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,583.98 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $895.19 | 2022-2025 | Xembify, Gamunex-C |
| Csl Behring | $645.72 | 2022-2025 | Hizentra, Andembry, Haegarda |
| Astrazeneca Pharmaceuticals LP | $400.33 | 2022-2024 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $327.99 | 2022-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $320.81 | 2023-2025 | |
| Pharming Healthcare, INC. | $162.57 | 2023-2025 | Joenja, Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $158.21 | 2023-2025 | Cuvitru, Takhzyro, Eohilia |
| Novartis Pharmaceuticals Corporation | $153.31 | 2023-2024 | |
| Amgen INC. | $129.14 | 2023-2025 | Tezspire |
| Pfizer INC. | $100.76 | 2024-2025 | |
| Greer Laboratories, INC. | $54.59 | 2025 | Oralair |
| Genentech USA, INC. | $30.95 | 2019-2024 | Xolair |
| Alk-Abello, INC | $30.55 | 2025 | Grastek, Ragwitek, Odactra |
| Ars Pharmaceuticals Operations, INC. | $29.86 | 2025 | Neffy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $19.86 | 2025 | Sajazir |
| Optinose US, INC. | $18.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Heath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.